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Summary We have shown that a number of anticonvulsant drugs can reduce glutamate release
at synapses in the rat entorhinal cortex (EC) in vitro. We have also shown that presynaptic NMDA
receptors (NMDAr) tonically facilitate glutamate release at these synapses. In the present study
we determined whether, phenytoin, gabapentin and felbamate may reduce glutamate release
by blocking the presynaptic NMDAr. Whole cell patch clamp recordings of spontaneous excita-
tory postsynaptic currents (sEPSCs) were used as a monitor of presynaptic glutamate release.
Postsynaptic NMDAr were blocked with internal dialysis with an NMDAr channel blocker. TheGabapentin antagonist, 2-AP5, reduced the frequency of sEPSCs by blocking the presynaptic facilitatory
NMDAr, but did not occlude a reduction in sEPSC frequency by gabapentin or phenytoin. Felba-
mate also reduced sEPSC frequency, but this effect was occluded by prior application of 2-AP5.
Thus, whilst all three drugs can reduce glutamate release, only the action of felbamate seems
to be due to interaction with presynaptic NMDAr.
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Introduction
Experiments in this laboratory have shown that the
Open acanticonvulsant drugs phenytoin, lamotrigine, gabapentin,
pregabalin and valproate can reduce the spontaneous
release of glutamate from excitatory terminals in the rat
entorhinal cortex (EC) in vitro (Cunningham and Jones,
∗ Corresponding author. Tel.: +44 1225 383935;
fax: +44 1225 386114.
E-mail address: r.s.g.jones@bath.ac.uk (R.S.G. Jones).
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Open access under CC BY license.000; Cunningham et al., 2000, 2003, 2004). The effect
f valproate alone appeared to depend on blockade of
oltage-gated sodium channels (VGSC; Cunningham et al.,
003), whereas the reduction in release elicited by the other
rugs was independent of any action on sodium channels.
abapentin and pregabalin appeared to act partly via an
ction on voltage-gated calcium channels (VGCC), and partly
ia an unknown mechanism (Cunningham et al., 2004).
nder CC BY license.We have also previously shown that glutamate release in
he EC is tonically facilitated by ambient glutamate acting
ia presynaptic NMDA autoreceptors (Berretta and Jones,
996a; Woodhall et al., 2001; Yang et al., 2006), an effect
onﬁrmed in visual cortex (Li and Han, 2007). Recently,
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t has been suggested that gabapentin may interact with
resynaptic NMDA receptors (NMDAr) in the hippocampus
Suarez et al., 2005). Furthermore, pregabilin has been sug-
ested to reduce GABA and, possibly, glutamate release
n hippocampal cultures via an interaction with presynap-
ic NMDAr (Micheva et al., 2006). There is some evidence,
lbeit scant, to suggest that phenytoin may block NMDAr
e.g. Wamil and McLean, 1993; Naskar et al., 2002), and
hat it may reduce NMDAr-stimulated monoamine transmit-
er release (Sethy and Sage, 1992; Brown et al., 1994). Thus,
e have considered the possibility that the reduction of glu-
amate release by anticonvulsants in the EC may depend on
lockade of presynaptic facilitatory NMDAr.
To investigate this possibility we monitored glutamate
elease in rat EC slices by recording spontaneous exci-
atory postsynaptic currents (sEPSCs) mediated by AMPA
eceptors (AMPAr) using whole-cell voltage clamp record-
ngs. When postsynaptic NMDAr are blocked by inclusion of
K-801 in the patch pipette, competitive NMDAr antago-
ists reduce the frequency (but not amplitude or kinetics)
f sEPSCs, by blocking the tonic presynaptic facilitation of
elease (Berretta and Jones, 1996a; Woodhall et al., 2001;
ang et al., 2006; Li and Han, 2007). Thus, we determined
hether the reduction in frequency of sEPSCs by phenytoin
nd gabapentin (Cunningham et al., 2000, 2004) could be
ccluded by prior blockade of presynaptic NMDAr. We com-
ared the effects of these two drugs to those of felbamate,
second-generation anticonvulsant. Felbamate has consis-
ently been shown to block NMDAr-mediated currents (e.g.
arty and Rogawski, 2000; Kuo et al., 2004), so could also
otentially alter glutamate release via an action at presy-
aptic NMDAr.
The results suggest that neither the VGSC-independent
eduction of glutamate release by phenytoin, nor the VGCC-
ndependent effect of gabapentin, are due to blockade of
he presynaptic NMDAr. However, felbamate does appear to
educe release via presynaptic NMDAr blockade, and this
ould be a factor in its anticonvulsant effect.
ethods
ombined entorhinal-hippocampal slices were prepared from male
istar rats, as previously described (Jones and Heinemann, 1988).
ats were killed by cervical dislocation. They were decapitated and
he brain was rapidly removed and immersed in oxygenated artiﬁ-
ial cerebrospinal ﬂuid (ACSF) chilled to 4 ◦C. Slices (450m) were
ut using a Vibroslice, and stored in ACSF bubbled with 95% O2/5%
O2, at room temperature. Following recovery for at least 1 h, indi-
idual slices were transferred to a recording chamber mounted on
he stage of a Zeiss Axioskop FS microscope. The chamber was per-
used (2ml/min) with oxygenated ACSF (pH 7.4) at 30—32 ◦C. The
CSF contained (in mM): NaCl (126), KCl (3.25), NaH2PO4 (1.25),
aHCO3 (24), MgSO4 (2), CaCl2 (2), and D-glucose (10). Neurones
ere visualized using differential interference contrast optics and
n infrared video camera.
Patch pipettes (1—4M) were pulled from borosilicate glass on
Flaming/Brown microelectrode puller. Pipettes were ﬁlled with a
olution containing (in mM): Cs-gluconate (100), HEPES (40), QX-314
1), EGTA (0.6), NaCl (4), MgCl2 (5), TEA-Cl (1), ATP-Na (4), GTP-
a (0.3), MK-801 (1). The solution was adjusted to 275mOsmol by
ilution, and set to pH 7.3 with CsOH. Whole cell voltage clamp
ecordings were made from neurones in layer V of the medial
ivision of the EC, using an Axopatch 200B ampliﬁer. Using this
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ipette solution and with membrane potential clamped at −60mV,
eurones displayed sEPSCs. The open channel blocker, MK-801,
as included in the patch pipette in order to block postsynap-
ic NMDAr in the recorded neurone. To facilitate this blockade,
eurones were depolarised to −10mV for 10 s at intervals (every
0 s) during a 10min period following breakthrough to whole-cell
ccess. Using this approach NMDAr mediated EPSCs are rapidly
bolished.
The use of intracellular MK-801 to block postsynaptic responses
as been described in detail by us previously (Berretta and Jones,
996a; Woodhall et al., 2001; Yang et al., 2006). Fig. 1 shows an
xperiment that conﬁrms the ability of MK-801 to block postsynap-
ic NMDAr. In this case, EPSCs were evoked (eEPSC) by electrical
timulation in layer V of the lateral EC, with MK-801 in the patch
ipette, and at a holding potential of −60mV (Fig. 1A). Blockade
f AMPA and GABA receptors left a small shallow eEPSC. When the
olding potential was changed to +40mV (Fig. 1B), this was revealed
s a large slow NMDAr mediated eEPSC. The holding potential was
hen stepped repetitively from −60 to −10mV (for just 5min in this
ase), and subsequent stimulation at +40mV showed that the eEPSC
as now abolished. This approach has become a widely accepted
eans of selectively blocking postsynaptic NMDAr, leaving presynap-
ic receptors intact, and has been used successfully by a number of
ther groups in cortical, hippocampal and amygdala neurones (e.g.
jostrom et al., 2003; Massey et al., 2004; Samson and Pare, 2005;
ender et al., 2006; Jourdain et al., 2007; Li and Han, 2007).
Even when postsynaptic receptors are not blocked with MK-801,
pontaneous events mediated solely by NMDAr are very infrequent,
nd there is only a minor contribution of NMDAr to the decay phase
f sEPSCs (Berretta and Jones, 1996b). In these circumstances, sEP-
Cs are abolished by bath application of NBQX and 2-AP5 (e.g.
tacey et al., 2002). Fig. 1C shows recordings of sEPSCs in one
eurone and conﬁrms that with postsynaptic NMDAr blocked with
ntracellular MK-801, addition of an AMPAr antagonist abolishes all
pontaneous currents. It should be stressed that all the recordings
resented in this paper were conducted with postsynaptic NMDAr
locked and under these experimental conditions, sEPSCs are medi-
ted by glutamate acting at AMPA receptors (Berretta and Jones,
996b; Woodhall et al., 2001). In other experiments in this lab-
ratory (Chamberlain, S.E.L., Jones, R.S.G.) we have shown that
ainate receptors can mediate postsynaptic excitatory responses
n the EC, but these receptors are not activated by spontaneously
eleased glutamate. Thus, sEPSCs in our recordings are mediated
olely by AMPAr.
The experimental protocols required patch clamp recordings for
eriods of up to 60min, so we had to consider the possibility that
hanges in sEPSCs might be complicated by run-down of events.
owever, the inclusion of ATP-Na and GTP-Na largely precluded this,
nd we have previously made similar long duration patch clamp
ecordings of sEPSCs in many studies without any problems regard-
ng stability (e.g. Berretta and Jones, 1996a,b; Cunningham et al.,
000, 2003, 2004; Cunningham and Jones, 2000; Evans et al., 2001;
oodhall et al., 2001; Stacey et al., 2002; Yang et al., 2006). Series
esistance compensation was not employed in the present experi-
ents, but access resistance (10—30M) was monitored at regular
ntervals throughout and neurones were discarded from analysis if
t changed by more than ±10%. Liquid junction potentials were esti-
ated using the calculator of pClamp 8 software, and compensated
or in the holding potentials.
After gaining whole cell access, and allowing time for MK-801
o diffuse into the neurone and block the postsynaptic NMDAr (with
epeated depolarizations), the neurone was then allowed to sta-
ilize for a further control period of not less than 10min after
hich sEPSCs were recorded. 2-AP5 was then added to the per-
usion medium for a period of 20min before further addition of an
nticonvulsant and perfusion of both drugs for a further 20min.
n a second series of experiments, the drugs were perfused in
everse order. sEPSCs were recorded throughout and analysis peri-
Felbamate but not phenytoin or gabapentin
Figure 1 Intracellular MK-801 blocks postsynaptic NMDAr. (A)
The traces are voltage clamp recordings of eEPSCs in a layer V
neurone (at least eight responses averaged) evoked by electri-
cal stimulation of afferent pathways at 0.05Hz. The large eEPSC
seen at a holding potential of −60mV, is replaced by a weak
slow eEPSC during perfusion with NBQX (10M) and bicuculline
(30M). (B) Shifting the holding potential to +40mV revealed a
large slow eEPSC that was subsequently abolished by a period of
repetitive depolarizing steps from −60 to −10mV over a period
of 5min. (C) Whole cell voltage clamp records of sEPSCs in a dif-
ferent layer V neurone. The three traces are continuous. The
patch pipette contained MK-801, and prior to the recordings
illustrated, the neurone had been subject to a series of depo-
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tlarizing voltage steps (as described above and in the text) for
a period of 10min. Addition of NBQX to the perfusion medium
(during red bar) rapidly abolished all sEPSCs.
ods conﬁned to the ﬁnal 5min of perfusion with one, and then both
drugs.Data were recorded to computer hard disk using Axoscope
software. Minianalysis (Synaptosoft, U.S.A.) was used for analy-
sis of sEPSCs off-line. sEPSCs were detected automatically using
a threshold-crossing algorithm. Threshold varied from neurone to
neurone, but was always maintained at a constant level in each
p
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ndividual recording. 200 sEPSCs were sampled during a contin-
ous recording period for each neurone under each condition.
he populations of events sampled were mixed, and represent
oth activity-dependent and activity-independent miniature EPSCs
mEPSCs) from multiple terminals on the same neurones, although
he majority of events (around 60—70%) are mEPSCs (see Berretta
nd Jones, 1996b). No attempt was made to separate these in the
resent study, but we have previously shown that presynaptic NMDAr
an facilitate both forms of release (Berretta and Jones, 1996a,b;
oodhall et al., 2001), and also that phenytoin and gabapentin
epress the frequency of both sEPSCs, and mEPSCs recorded in
he presence of TTX (Cunningham et al., 2000, 2004). To compare
ooled data under control and drug conditions we determined mean
nter-event interval (IEI), the frequency derived from the IEI, ampli-
ude, and rise and decay times for sEPSCs in each cell. A paired
-test was used to compare mean amplitudes and frequencies, rise
nd decay times, and the non-parametric Kolmogorov—Smirnoff (KS)
est to assess the signiﬁcance of shifts in cumulative probability dis-
ributions of IEI. All error values stated in the text refer to standard
rror of the mean.
The following drugs were used: 2-AP5 (D,L-2-amino-5-
hosphonovalerate; Tocris, UK); phenytoin sodium (Sigma, UK);
abapentin (1-(aminomethyl)cycloheaneacetic acid; a gift from
ﬁzer, Global Research & Development, Ann Arbor, Michigan);
elbamate (2-phenyl-1,3-propanediol dicarbamate; Tocris, UK).
esults
xperiments were performed on a total of 21 neu-
ones in layer V of the medial EC. sEPSCs in control
ecordings had a mean IEI of 291± 44ms (equating to a
requency of 5.3± 0.7Hz), an amplitude of 12.0± 0.9 pA,
nd rise (10—90%) and decay times (60%) of 1.9± 0.1 and
.8± 0.9ms, respectively.
henytoin
n three neurones, perfusion with 2-AP5 (50M) increased
he mean IEI of sEPSCs from 211± 66 to 327± 117ms
reﬂecting a decrease in frequency from 6.5± 2.9 to
.2± 1.7Hz, P < 0.01), with no signiﬁcant change in ampli-
ude (10.2± 1.0 pA versus 12.2± 1.7 pA). The decrease in
requency without change in amplitude or kinetics (see
elow) is strongly indicative of a presynaptic effect, and, as
e have previously demonstrated, reﬂects blockade of the
onic facilitation of glutamate release via the presynaptic
MDA autoreceptor (Berretta and Jones, 1996a; Woodhall
t al., 2001). In the same neurones, subsequent addition of
henytoin (50M in the presence of 2-AP5) caused a fur-
her increase in IEI to 459± 175ms (3.4± 1.6Hz, P < 0.05),
gain without change in amplitude. Fig. 2A shows examples
f voltage clamp recordings from one neurone, and cumula-
ive probability analysis of IEI in pooled data from all three
eurones (Fig. 2B). There was a shift towards longer inter-
als in the presence of 2-AP5, and a further shift to the
ight with the addition of phenytoin. On average, the fre-
uency of sEPSCs was reduced by −37± 8% by 2-AP5. With
he addition of the anticonvulsant the total reduction com-
ared to control was −55± 3%. Comparing the frequency
f events in phenytoin plus 2-AP5 to 2-AP5 alone gave an
verage reduction of −21± 4%. sEPSC rise times (10—90%)
ere 2.0± 0.4ms in control, 2.1± 0.2ms in the presence of
-AP5, and 2.6± 0.6ms with subsequent addition of pheny-
160
Figure 2 Phenytoin does not act via presynaptic NMDAr. (A)
Voltage clamp recordings from a single layer V neurone. The
downward defections are spontaneous sEPSCs mediated via
glutamate acting at postsynaptic AMPAr. Application of 2-AP5
(50M) reduced the frequency of sEPSCs, but did not occlude
the effect of the subsequent addition of phenytoin (50M),
which caused a substantial further reduction. (B) Pooled data
from three neurones (200 events from each neurone in each
condition). The cumulative probability curve in the presence
of 2-AP5 is signiﬁcantly (P < 0.01) shifted to the right towards
longer intervals (lower frequency). The addition of phenytoin
caused a further signiﬁcant shift (KS, P < 0.001). (C) In the
reverse experiment, phenytoin signiﬁcantly increased IEI (KS,
P < 0.001), and 2-AP5 caused a further signiﬁcant shift to the
right (KS, P < 0.001). Pooled data from four neurones.
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oin. Corresponding times to 60% decay were 5.1± 2.0,
.6± 2.3 and 5.4± 1.4ms, respectively.
We conducted the reverse experiment in a further four
eurones. Phenytoin, applied alone, increased IEI from
63± 36 to 250± 43ms, and subsequent perfusion with 2-
P5 resulted in a further increase in IEI to 630± 258ms. The
espective changes in sEPSC frequency were from 7.8± 2.5
o 4.6± 1.1 (P = 0.05) with phenytoin, and to 2.4± 0.8%
P < 0.01) on addition of 2-AP5. Again, there were no changes
n amplitude (not shown). The pooled cumulative probabil-
ty analysis for IEI data are illustrated in Fig. 2C, showing
learly the shift towards longer intervals in phenytoin, and
further shift when 2-AP5 was added. The mean reductions
n sEPSC frequency were −37± 4% with phenytoin alone, and
71± 7% when both drugs were present. This corresponds
o a decrease in frequency of −47± 10% when comparing
henytoin alone to phenytoin plus 2-AP5.
Rise times (control 1.5± 0.1ms; phenytoin 2.1± 0.5ms;
henytoin plus 2-AP5 1.8± 0.4ms) and decay times
5.3± 0.3ms versus 5.4± 0.2ms versus 5.3± 0.3ms) were
gain unaltered.
elbamate
n three neurones 2-AP5 (50M) again reduced gluta-
ate release, reﬂected by an increase in mean IEI
from 522± 154 to 950± 325ms; frequency 2.1± 0.6 to
.2± 0.3Hz, P < 0.05) with no obvious change in sEPSC
mplitude (13.5± 3.1 pA versus 12.5± 1 pA). However, sub-
equent addition of felbamate (100M), elicited no further
hange in IEI (883± 277ms). In fact, in two neurones,
EPSC frequency was slightly increased when felbamate
as added, although overall there was no marked change
1.3± 0.3Hz, P > 0.1), and again amplitude remained about
he same (12.6± 1.2Hz). Fig. 3A shows voltage clamp
ecordings from one neurone and the cumulative probability
nalysis of pooled data are illustrated in Fig. 3B. sEPSC rise
imes were unaltered at 2.0± 0.4ms in control, 2.4± 0.3ms
n the presence of 2-AP5, and 2.5± 0.4ms with the addi-
ion of felbamate. Corresponding times to 60% decay were
.3± 1.8, 6.0± 1.2 and 5.8± 1.9ms, respectively.
The reverse experiment was conducted in four neurones
nd gave very similar results. Felbamate alone decreased
PSC frequency from 5.1± 1.1 to 2.5± 0.9Hz (P < 0.01), IEI
ncreasing from 238± 67ms versus 587± 193ms. Now, addi-
ion of 2-AP5 failed to cause any signiﬁcant further change
2.6± 0.9Hz; 528± 140ms). The pooled cumulative proba-
ility data for IEI from the four neurones can be seen in
ig. 3C. Mean amplitudes were essentially the same through-
ut (11.2± 3.8 pA versus 10.7± 4.1 pA versus 11.2± 4.5 pA).
ise times were also unaltered (control 2.2± 0.6ms; felba-
ate 2.2± 0.7ms; felbamate plus 2-AP5 2.4± 0.6ms), as
ere decay times (4.8± 0.6ms versus 4.7± 0.7ms versus
.4± 0.5ms.
The normalised data supported the observation that the
MDA antagonist and the anticonvulsant could occlude each
ther’s effects. Thus, application of 2-AP5 reduced sEPSC
requency by −48± 3%, and the percentage reduction in the
resence of both 2-AP5 and felbamate was virtually the same
t −43± 1%. When the effect of felbamate was normalised
o the frequency in 2-AP5, there was a slight increase to
Felbamate but not phenytoin or gabapentin
Figure 3 Felbamate acts via the presynaptic NMDAr. Details
as in Fig. 1. (A) 2-AP5 (50M) reduces sEPSC frequency but the
addition of felbamate (100M) has no further effect. (B) This is
conﬁrmed by pooled data for IEI in three neurones where there
was a signiﬁcant (KS, P < 0.001) rightward shift in the cumulative
probability curve in 2-AP5, but the distribution with the addi-
tion of felbamate is completely overlapping. (C) Similar data
were obtained in the reverse experiment in four neurones where
felbamate occluded 2-AP5.
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10± 5%. Application of felbamate alone in the second set
f experiments reduced frequency by −55± 9% and with
ddition of 2-AP5 the total reduction was −52± 8%. This
eﬂected a change of +7± 12% when 2-AP5 was normalised
o the frequency in felbamate alone.
abapentin
abapentin has been suggested to target presynaptic NMDAr
Suarez et al., 2005), so we compared its effects to those of
he other anticonvulsants. sEPSC frequency in three neu-
ones was signiﬁcantly (P < 0.05) reduced from 6.8± 2 to
.1± 1.4Hz (IEI: 188± 72ms versus 552± 290ms) during
erfusion with 2-AP5. Addition of gabapentin (25M) caused
further reduction (P < 0.05) to 1.6± 0.4Hz (693± 191ms).
mplitudes were not signiﬁcantly altered throughout
11.5± 2.5 pA versus 12.2± 4.2 pA versus 11.8± 4.2 pA),
s were rise times (1.6± 0.4ms versus 2.1± 0.8ms ver-
us 1.9± 0.3ms) and decay times (5.7± 0.6ms versus
.0± 0.8ms versus 5.6± 0.5ms). One study is illustrated in
ig. 4A, with pooled data from the three neurones sum-
arized in Fig. 4B. Similar results were obtained when
abapentin was applied prior to 2-AP5 (n = 4). In this case
EI was increased from 304± 85 to 712± 146ms by the
nticonvulsant (KS, P < 0.01) with a further increase to
049± 397ms when 2-AP5 was added (KS, P < 0.01). The
esults of the pooled IEI analysis are shown in Fig. 4C. As
n previous studies, rise times, decay times and amplitudes
ere unaltered throughout (not shown).
The normalised data also indicated a lack of occlu-
ion between the two drugs. Thus, 2-AP5 reduced sEPSC
requency by −45± 11% when applied alone and the
otal reduction with subsequent addition of gabapentin
as −60± 17%. Comparing 2-AP5 alone to 2-AP5 plus
abapentin gave an average reduction of −30± 18%. In the
everse experiments, gabapentin reduced sEPSC frequency
y −58± 5% and together with 2-AP5 the reduction was
68± 4%. Normalizing the 2-AP5 data to the frequency in
he presence of gabapentin gave a reduction of −21± 13%.
iscussion
he anticonvulsant effect of phenytoin has traditionally
een associated with its ability to exert a use- and
requency-dependent block of VGSC, thereby reducing sus-
ained repetitive ﬁring of action potentials in cortical
eurones (see Rogawski and Loscher, 2004). However, we
ave shown previously that phenytoin reduces the frequency
ut not amplitude of sEPSCs in the EC, suggesting that it also
cts presynaptically to reduce glutamate release. Moreover,
his effect persists in the presence of TTX, which suggests
hat it occurs independently of VGSC-blockade and we have
uggested that it occurs downstream of Ca-entry into glu-
amate terminals (Cunningham et al., 2000). We have also
hown that glutamate release is tonically facilitated by Ca-
ntry through presynaptic NMDAr in the EC (Woodhall et al.,
001), so we considered the possibility that reduction of
lutamate release could occur via blockade of this recep-
or. The current experiments suggest that this is unlikely to
e the case. The reduction in sEPSC frequency induced by
henytoin was not occluded by prior blockade of presynap-
162
Figure 4 (A—C) Gabapentin does not act via presynaptic
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2MDAr. Details as in Fig. 2. The effect of gabapentin (25M)
as very similar to that seen with phenytoin (Fig. 2) and differed
rom the occlusion seen with felbamate (Fig. 3).
ic NMDAr with 2-AP5 (nor vice versa). This argues strongly
gainst a role of blockade of the facilitatory autoreceptor
n the action of phenytoin at glutamate terminals.Thus, the VGSC-independent mechanism of phenytoin on
lutamate release therefore remains unknown. One possibil-
ty is that phenytoin interferes with the release mechanism
ia inhibition of PKC (see Cunningham et al., 2000). Another
ossibility is that it disrupts release via a direct action on
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he vesicles. For example, the novel anticonvulsant, leve-
iractem, binds speciﬁcally to the vesicle associated protein,
V2A (Lynch et al., 2004). It is conceivable that phenytoin
ay also act directly on the release process by altering the
xocytotic process.
The present study shows that felbamate, like the other
rugs we have tested previously (Cunningham et al., 2000,
003, 2004; Cunningham and Jones, 2000), reduces the
requency, but not amplitude, of sEPSCs in EC neurones,
uggesting a target on, or in, presynaptic glutamate termi-
als. Unlike phenytoin, however, this effect was completely
ccluded by pre-perfusion with 2-AP5, and the reverse
xperiment produced the same result. This clearly indi-
ates that felbamate can act to block presynaptic NMDAr
nd thereby reduce the tonic positive feedback facilitation
f glutamate release. This effect may not be completely
urprising in view of the fact that felbamate has repeat-
dly been shown to act as an NMDAr blocker (Rho et al.,
994; Subramaniam et al., 1995; Kuo et al., 2004), as a
esult of either an interaction with the glycine site of the
eceptor (e.g. White et al., 1995; Kuo et al., 2004) or as
result of open channel blockade (Subramaniam et al.,
995; Harty and Rogawski, 2000). Whatever its action, it is
igniﬁcant that it has shown to be more selective for NR1-
R2B heteromeric channels (Kleckner et al., 1999; Harty and
ogawski, 2000). This would agree with our previous studies,
hich have shown that the presynaptic NMDAr is likely to be
rimarily NR2B (Woodhall et al., 2001; Yang et al., 2006).
Felbamate has also been shown to block VGCC (Stefani
t al., 1996). This is unlikely to be involved in the reduc-
ion of glutamate release that we see, as it appears to be
peciﬁc for L-type channels, and glutamate release at EC
ynapses is likely to be mediated by a combination of N,
/Q and R type channels (Cunningham et al., 2004; Woodhall
t al., 2007). In addition, felbamate may also block VGSC
Taglialatela et al., 1996) leading to a reduction in sustained
epetitive ﬁring (White et al., 1992; Pisani et al., 1995), and
as also been suggested to enhance GABAAr mediated cur-
ents (Rho et al., 1994, 1997; Kume et al., 1996). Any, or
ll, of these effects could be involved in the anticonvulsant
ctions of felbamate, but our results suggest that a reduc-
ion of the positive feedback control of glutamate release
ia presynaptic NMDAr needs to be included in this panoply
f actions.
Suarez et al. (2005) recently suggested that presynap-
ic NMDAr on Schaffer-commissural ﬁbres increase axonal
xcitability in CA1 as a result of increased Na-entry via the
eceptor. This differs from the situation in the EC where
he facilitatory effect of presynaptic NMDAr on glutamate
elease is dependent on Ca-entry via the receptor ionophore
Woodhall et al., 2001). The present data also suggest that
he ability of gabapentin to block the presynaptic NMDAr
n the hippocampus is not reﬂected by a similar action in
he EC. Thus, the reduction in glutamate release we previ-
usly reported with gabapentin (Cunningham et al., 2004)
as not occluded by prior blockade of the receptor with
-AP5 (nor vice versa). Our previous data (Cunningham et
l., 2004) suggest that gabapentin may reduce glutamate
elease partly by blockade of Ca-entry via VGCC and partly
y an unknown mechanism. The current experiments sug-
est that the latter is unlikely to be linked to blockade of
resynaptic NMDAr. Whilst we cannot completely rule out
EH
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an action of gabapentin at the facilitatory autoreceptor, it
seems unlikely that this plays a major role in its anticonvul-
sant action.
In conclusion, we have shown that felbamate, like pheny-
toin, lamotrigine, gabapentin, pregabilin and valproate
(Cunningham and Jones, 2000; Cunningham et al., 2000,
2003, 2004), reduces the release of glutamate at excita-
tory synapses in the EC. However, in contrast to at least
two of these drugs, the action of felbamate seems to be
largely due to blockade of presynaptic facilitatory NMDA
autoreceptors. Thus, whilst a reduction in synaptic excita-
tion may be a common underlying mechanism involved in
anticonvulsant actions, different drugs may achieve this by
very different means. We have recently shown that there
is a developmental decline in the facilitation of glutamate
release by presynaptic NMDAr in the EC, but this effect
is reversed in the cortex of chronically epileptic animals
(Yang et al., 2006). Thus, enhanced NMDAr mediated glu-
tamate release could well contribute to epileptogenesis,
and the ability of felbamate to block this might be a very
important aspect of its anticonvulsant actions. Although the
present data suggest that other drugs such as phenytoin
and gabapentin do not appear to exert such an action in
normal cortex, it is possible that this could change in the
pathological condition. Future experiments will address this
issue.
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